C4 Therapeutics, Inc. (CCCC)

Growth Investors: Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 16%

Shareholders in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) may be thrilled to learn that the analysts have just delivered a...

• 
  Earnings Beat: Benson Hill, Inc. (NYSE:BHIL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

  Simply Wall St.
• 
  These Analysts Just Made A Massive Downgrade To Their Purple Innovation, Inc. (NASDAQ:PRPL) EPS Forecasts

  Simply Wall St.

Analysts Are Upgrading C4 Therapeutics, Inc. (NASDAQ:CCCC) After Its Latest Results

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) just released its latest quarterly results and things are looking bullish...

• 
  US$3.75 - That's What Analysts Think PaySign, Inc. (NASDAQ:PAYS) Is Worth After These Results

  Simply Wall St.
• 
  Analysts Just Shaved Their Finance Of America Companies Inc. (NYSE:FOA) Forecasts Dramatically

  Simply Wall St.

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 17.65% and 77.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?